



**Company Contact:**  
**Jie Du, Ph.D.**  
**President & CEO**  
**JDP THERAPEUTICS, INC.**  
**Email: [jiedu@jdptherapeutics.com](mailto:jiedu@jdptherapeutics.com)**  
**[www.jdptherapeutics.com](http://www.jdptherapeutics.com)**

## **JDP Announces Notice of Allowance for Its 4th Patent Covering JDP-205**

**BLUE BELL, PENNSYLVANIA, May 15, 2015** – JDP Therapeutics Inc., a privately held late stage specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers JDP's lead product JDP-205 and other related products, further expanding the intellectual property portfolio for the company's lead assets, which are currently in Phase III clinical trials. This is the 4th Patent for the company for its JDP-205 and its related products. This Notice of Allowance is for JDP's Patent Application Serial Number 13/559,954 titled "Non-sedating Antihistamine Injection Formulations and Methods of Use thereof". The allowed patent claims a new method of use of JDP's lead product JDP-205 for the treatment of acute allergic reactions. This newly allowed patent will protect JDP-205, with its patent coverage term, through year 2030. With the FDA's review extension, the patent term may be extended beyond 2031 or further.

"The grant of this 4th patent is a great milestone for us", stated Dr. Jie Du, Chief Executive Officer of JDP, "This patent is part of the company's expanding IP portfolio covering JDP-205 and other related products. The company is currently prosecuting 5 additional pending U.S. and international patent applications to protect the commercial potential of JDP-205 and related products to year 2030 and beyond."

### **About JDP-205**

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years. JDP-205 is projected to have a significant commercial opportunity with its peak annual sales in the range of ~\$300MM.

**About JDP Therapeutics Inc.**

JDP Therapeutics Inc. is a privately held, clinical phase III stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email [info@jdptherapeutics.com](mailto:info@jdptherapeutics.com)

###

*Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.*